Loading…

The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review

Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have em...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical laboratory analysis 2024-01, Vol.38 (1-2), p.e25005-n/a
Main Authors: Hoseinnezhad, Taraneh, Soltani, Nasrin, Ziarati, Sarina, Behboudi, Emad, Mousavi, Mohammad Javad
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423
cites cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423
container_end_page n/a
container_issue 1-2
container_start_page e25005
container_title Journal of clinical laboratory analysis
container_volume 38
creator Hoseinnezhad, Taraneh
Soltani, Nasrin
Ziarati, Sarina
Behboudi, Emad
Mousavi, Mohammad Javad
description Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes. Methods In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity. Results Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations. Conclusion Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants. This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effe
doi_str_mv 10.1002/jcla.25005
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10829690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2917552913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</originalsourceid><addsrcrecordid>eNp9kctOGzEUhi1UBCllwwNUlthUVQd8GSd2N1WUXgBFYhN1a3k8Z4IjZ5zaM0HZ9RF4Rp6kDgEELLrxsfR_-nSOfoROKDmjhLDzhfXmjAlCxB4aUKJkwSQT79CASDkqJKH8EL1PaUEIkYoOD9AhzzmVlA7QfHYDOAYPODT4YjrGc2ihcxavTXSm7RJ2LZ5c_778fv_3jiqc-mRh1bnKeddtvuAEa4gPP9PWeBliZ7bBV5xNPlTG4whrB7cf0H5jfILjx3mEZj9_zCYXxfT61-VkPC1sWSpRVJzWDS-JFaUsVUNEoyhYVSnZlLVgktd0yC2w2jaVGVXDEbc54awSoGTJ-BH6ttOu-moJtYW2i8brVXRLEzc6GKdfJ6270fOw1pRIpoaKZMOnR0MMf3pInV66fLL3poXQJ80UHQmRX57R0zfoIvSxzedlihEquRJlpj7vKBtDShGa520o0dv-9LY__dBfhj--3P8ZfSosA3QH3DoPm_-o9NVkOt5J_wFWPKXe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920183954</pqid></control><display><type>article</type><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><source>Open Access: PubMed Central</source><source>Wiley_OA刊</source><source>ProQuest - Publicly Available Content Database</source><creator>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</creator><creatorcontrib>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</creatorcontrib><description>Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes. Methods In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity. Results Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations. Conclusion Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants. This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</description><identifier>ISSN: 0887-8013</identifier><identifier>ISSN: 1098-2825</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.25005</identifier><identifier>PMID: 38251811</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Alleles ; Antigens ; COVID-19 ; COVID-19 - genetics ; COVID-19 vaccines ; disease outcomes ; Disease transmission ; ethnicity ; Gene frequency ; Gene Frequency - genetics ; Genetic diversity ; genetic variation ; Histocompatibility antigen HLA ; HLA alleles ; Humans ; Immune system ; Lymphocytes ; Mortality ; Pandemics ; Peptides ; Polymorphism ; Population genetics ; Proteins ; Review ; SARS-CoV-2 - genetics ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; severity ; Signal transduction ; susceptibility ; Therapeutic applications ; Viruses</subject><ispartof>Journal of clinical laboratory analysis, 2024-01, Vol.38 (1-2), p.e25005-n/a</ispartof><rights>2024 The Authors. published by Wiley Periodicals LLC.</rights><rights>2024 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</citedby><cites>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</cites><orcidid>0000-0002-1296-4558 ; 0000-0002-8971-0775</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2920183954/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2920183954?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11560,25751,27922,27923,37010,37011,44588,46050,46474,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38251811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoseinnezhad, Taraneh</creatorcontrib><creatorcontrib>Soltani, Nasrin</creatorcontrib><creatorcontrib>Ziarati, Sarina</creatorcontrib><creatorcontrib>Behboudi, Emad</creatorcontrib><creatorcontrib>Mousavi, Mohammad Javad</creatorcontrib><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes. Methods In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity. Results Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations. Conclusion Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants. This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</description><subject>Alleles</subject><subject>Antigens</subject><subject>COVID-19</subject><subject>COVID-19 - genetics</subject><subject>COVID-19 vaccines</subject><subject>disease outcomes</subject><subject>Disease transmission</subject><subject>ethnicity</subject><subject>Gene frequency</subject><subject>Gene Frequency - genetics</subject><subject>Genetic diversity</subject><subject>genetic variation</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA alleles</subject><subject>Humans</subject><subject>Immune system</subject><subject>Lymphocytes</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Peptides</subject><subject>Polymorphism</subject><subject>Population genetics</subject><subject>Proteins</subject><subject>Review</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>severity</subject><subject>Signal transduction</subject><subject>susceptibility</subject><subject>Therapeutic applications</subject><subject>Viruses</subject><issn>0887-8013</issn><issn>1098-2825</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kctOGzEUhi1UBCllwwNUlthUVQd8GSd2N1WUXgBFYhN1a3k8Z4IjZ5zaM0HZ9RF4Rp6kDgEELLrxsfR_-nSOfoROKDmjhLDzhfXmjAlCxB4aUKJkwSQT79CASDkqJKH8EL1PaUEIkYoOD9AhzzmVlA7QfHYDOAYPODT4YjrGc2ihcxavTXSm7RJ2LZ5c_778fv_3jiqc-mRh1bnKeddtvuAEa4gPP9PWeBliZ7bBV5xNPlTG4whrB7cf0H5jfILjx3mEZj9_zCYXxfT61-VkPC1sWSpRVJzWDS-JFaUsVUNEoyhYVSnZlLVgktd0yC2w2jaVGVXDEbc54awSoGTJ-BH6ttOu-moJtYW2i8brVXRLEzc6GKdfJ6270fOw1pRIpoaKZMOnR0MMf3pInV66fLL3poXQJ80UHQmRX57R0zfoIvSxzedlihEquRJlpj7vKBtDShGa520o0dv-9LY__dBfhj--3P8ZfSosA3QH3DoPm_-o9NVkOt5J_wFWPKXe</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Hoseinnezhad, Taraneh</creator><creator>Soltani, Nasrin</creator><creator>Ziarati, Sarina</creator><creator>Behboudi, Emad</creator><creator>Mousavi, Mohammad Javad</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1296-4558</orcidid><orcidid>https://orcid.org/0000-0002-8971-0775</orcidid></search><sort><creationdate>202401</creationdate><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><author>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alleles</topic><topic>Antigens</topic><topic>COVID-19</topic><topic>COVID-19 - genetics</topic><topic>COVID-19 vaccines</topic><topic>disease outcomes</topic><topic>Disease transmission</topic><topic>ethnicity</topic><topic>Gene frequency</topic><topic>Gene Frequency - genetics</topic><topic>Genetic diversity</topic><topic>genetic variation</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA alleles</topic><topic>Humans</topic><topic>Immune system</topic><topic>Lymphocytes</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Peptides</topic><topic>Polymorphism</topic><topic>Population genetics</topic><topic>Proteins</topic><topic>Review</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>severity</topic><topic>Signal transduction</topic><topic>susceptibility</topic><topic>Therapeutic applications</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoseinnezhad, Taraneh</creatorcontrib><creatorcontrib>Soltani, Nasrin</creatorcontrib><creatorcontrib>Ziarati, Sarina</creatorcontrib><creatorcontrib>Behboudi, Emad</creatorcontrib><creatorcontrib>Mousavi, Mohammad Javad</creatorcontrib><collection>Wiley_OA刊</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoseinnezhad, Taraneh</au><au>Soltani, Nasrin</au><au>Ziarati, Sarina</au><au>Behboudi, Emad</au><au>Mousavi, Mohammad Javad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2024-01</date><risdate>2024</risdate><volume>38</volume><issue>1-2</issue><spage>e25005</spage><epage>n/a</epage><pages>e25005-n/a</pages><issn>0887-8013</issn><issn>1098-2825</issn><eissn>1098-2825</eissn><abstract>Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes. Methods In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity. Results Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations. Conclusion Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants. This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>38251811</pmid><doi>10.1002/jcla.25005</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1296-4558</orcidid><orcidid>https://orcid.org/0000-0002-8971-0775</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-8013
ispartof Journal of clinical laboratory analysis, 2024-01, Vol.38 (1-2), p.e25005-n/a
issn 0887-8013
1098-2825
1098-2825
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10829690
source Open Access: PubMed Central; Wiley_OA刊; ProQuest - Publicly Available Content Database
subjects Alleles
Antigens
COVID-19
COVID-19 - genetics
COVID-19 vaccines
disease outcomes
Disease transmission
ethnicity
Gene frequency
Gene Frequency - genetics
Genetic diversity
genetic variation
Histocompatibility antigen HLA
HLA alleles
Humans
Immune system
Lymphocytes
Mortality
Pandemics
Peptides
Polymorphism
Population genetics
Proteins
Review
SARS-CoV-2 - genetics
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
severity
Signal transduction
susceptibility
Therapeutic applications
Viruses
title The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A43%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20HLA%20genetic%20variants%20in%20COVID%E2%80%9019%20susceptibility,%20severity,%20and%20mortality:%20A%20global%20review&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Hoseinnezhad,%20Taraneh&rft.date=2024-01&rft.volume=38&rft.issue=1-2&rft.spage=e25005&rft.epage=n/a&rft.pages=e25005-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.25005&rft_dat=%3Cproquest_pubme%3E2917552913%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2920183954&rft_id=info:pmid/38251811&rfr_iscdi=true